Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

New combination approach may help crush resistance to treatment in lung cancer patients

New combination approach may help crush resistance to treatment in lung cancer patients

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix resubmits NDA for DEXTENZA

Coffee and the heart – four strong cups a day is beneficial finds study

Coffee and the heart – four strong cups a day is beneficial finds study

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Researchers use innovative method to screen kinases for cancer drug's effectiveness

Researchers use innovative method to screen kinases for cancer drug's effectiveness

Scientists synthesize new multifunctional compound that has anti-tumor properties

Scientists synthesize new multifunctional compound that has anti-tumor properties

Leading medical societies update molecular testing guideline for lung cancer

Leading medical societies update molecular testing guideline for lung cancer

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Overcoming Challenges of Assays of Complex Cellular Models with Real-Time Live-Cell Analysis

Overcoming Challenges of Assays of Complex Cellular Models with Real-Time Live-Cell Analysis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.